Ubiquinol Slows Motor Decline in Multiple System Atrophy Trial

The Search for Disease Modification in Multiple System Atrophy

Multiple system atrophy (MSA) presents a formidable clinical challenge characterized by rapid neurodegeneration and a historical lack of disease-modifying interventions [1]. While recent progress in Alzheimer’s disease has yielded monoclonal antibodies targeting amyloid, these advancements have not yet extended to the complex proteinopathies of atypical parkinsonism [2, 3]. The pathogenesis of MSA involves a multifaceted cascade of mitochondrial dysfunction, oxidative stress, and impaired proteostasis (the cellular mechanisms governing protein synthesis, folding, and degradation), often exacerbated by age-related biological shifts [4]. Furthermore, recent research identifies ferroptosis (a form of iron-dependent regulated cell death driven by lipid peroxidation) as a potential mechanism for neuronal loss [5, 6]. Although clinicians currently focus on symptomatic relief, a recent Phase 2 randomized controlled trial of ubiquinol demonstrated a significant reduction in motor progression compared to placebo, suggesting that targeting mitochondrial exhaustion may be a viable therapeutic strategy [1]. This review evaluates the clinical efficacy of repurposing established pharmacological agents to target these specific pathogenic pathways [1, 7].

Targeting Alpha-Synuclein and Neuroinflammation

The strategy of drug repurposing aims to shorten the timeline for therapeutic development by identifying existing agents that may inhibit the aggregation of alpha-synuclein, the protein that forms the toxic intracellular inclusions characteristic of MSA pathology. Investigators have evaluated several compounds for this purpose, including the mTOR inhibitor sirolimus (a drug that blocks the mechanistic target of rapamycin to modulate cell growth and autophagy), the antibiotic rifampicin, the mood stabilizer lithium, the tyrosine kinase inhibitor nilotinib, and epigallocatechin gallate (a polyphenol derived from green tea). While numerous repurposed agents showed efficacy in experimental models, these laboratory successes have largely failed to translate into meaningful clinical outcomes for patients. The transition from bench to bedside is often hindered by the biological complexity of the human central nervous system, which may not be fully captured in animal models of alpha-synucleinopathy.

Beyond protein aggregation, clinicians have targeted the neuroinflammatory response as a potential driver of neuronal loss in multiple system atrophy. Investigators have specifically evaluated the tetracycline antibiotic minocycline and intravenous immunoglobulin for their ability to modulate the immune response and reduce central nervous system inflammation. However, the results have been disappointing; most repurposed agents failed to demonstrate significant disease-slowing effects in clinical trials. This discrepancy between success in MSA experimental models and failure in human subjects may be attributed to several factors, including small sample sizes, the enrollment of patients already in the late stages of the disease, and significant tolerability issues, such as those observed in trials involving lithium. For the practicing clinician, these results underscore the difficulty of arresting an established inflammatory cascade once neurodegeneration is widespread.

Mitochondrial Support and Neurotrophic Signaling

Beyond protein aggregation and inflammation, clinicians are investigating therapies that address mitochondrial dysfunction and excitotoxicity (the process where overstimulation of neurotransmitter receptors, particularly glutamate, leads to neuronal damage). This therapeutic strategy focuses on stabilizing cellular energy production and preventing the metabolic collapse of neurons. Specific agents evaluated for their potential to mitigate these pathways include the antioxidant ubiquinol, the monoamine oxidase B inhibitors rasagiline and safinamide, and the glutamate antagonist riluzole. While these compounds aim to preserve the metabolic integrity of the central nervous system, most have historically struggled to translate their biochemical mechanisms into measurable clinical benefits for patients with multiple system atrophy.

Another area of active research involves the restoration of neurotrophic support, which refers to the biological signaling factors that promote the survival, growth, and maintenance of neurons. Researchers have explored the repurposing of several agents to bolster these protective signals, including fluoxetine and other selective serotonin reuptake inhibitors, as well as metabolic regulators such as insulin and the glucagon like peptide 1 receptor agonist exendin-4 (a class of medication typically used in type 2 diabetes that has shown neuroprotective potential). Despite the theoretical basis for these interventions, clinical evidence for their efficacy remained limited until the recent emergence of ubiquinol as a notable exception to the trend of failed trials. In a Phase 2 randomized controlled trial, investigators found that ubiquinol led to a significant reduction in motor progression compared to placebo. This finding is particularly significant for clinical practice because it represents the first placebo-controlled evidence of disease modification in multiple system atrophy, suggesting that targeting mitochondrial health may offer a viable path toward altering the natural history of this progressive disorder.

Overcoming Barriers in Clinical Trial Design

Multiple system atrophy is a rapidly progressive neurodegenerative disorder that currently lacks any proven disease-modifying therapy, and historical trials in this population have faced significant hurdles. Researchers have identified several critical limitations in past study designs, including small sample sizes that lacked the statistical power to detect treatment effects and the enrollment of patients in late stages of the disease when neurodegeneration may be too advanced to arrest. Furthermore, poor drug tolerability has frequently led to high attrition rates; for instance, trials investigating lithium were hampered by significant side effects that limited its clinical utility in this population. These failures highlight the need for earlier intervention and more tolerable therapeutic regimens.

To address these historical challenges, the field is shifting toward more robust methodologies. Ongoing studies and emerging approaches, such as combination therapies that target multiple pathogenic pathways simultaneously, are currently being explored to improve patient outcomes. Experts emphasize that the continued exploration of repurposed therapies, alongside improved trial design and the development of biomarkers (measurable biological indicators used to track disease progression or treatment response), is warranted to achieve a definitive disease-modifying treatment. This strategy of drug repurposing remains a vital pathway for clinicians because it utilizes agents originally approved for other indications to accelerate development. By bypassing the lengthy early-stage safety testing required for entirely new compounds, researchers can more rapidly evaluate whether existing medications can be applied to the urgent needs of patients with multiple system atrophy.

References

1. Jeong SH, Shin JY, Lee PH. Drug repurposing for disease-modifying effects in multiple system atrophy.. Translational neurodegeneration. 2026. doi:10.1186/s40035-026-00551-7

2. Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01911-3

3. Huang L, Kuan Y, Lin H, Hu C. Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. Journal of Biomedical Science. 2023. doi:10.1186/s12929-023-00976-6

4. Guo J, Huang X, Dou L, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-01251-0

5. Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01969-z

6. Alves F, Lane DJ, Nguyen TPM, Bush AI, Ayton S. In defence of ferroptosis. Signal Transduction and Targeted Therapy. 2025. doi:10.1038/s41392-024-02088-5

7. Ma Y, Tian H, Xiao W, et al. Machine Learning Approaches for Optimizing Drug Combinations in Neurodegenerative Diseases: A Brief Review.. ACS omega. 2025. doi:10.1021/acsomega.5c07349